Author

Shanshan Zheng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma

Findings identify MYC-driven transcription as a therapeutic vulnerability in CIC -rearranged sarcoma and support combined CDK2 and CDK9 inhibition as a promising treatment strategy.

Quentin Odom-Lewis, Samantha L. Davis, Stephan Pieper et al. · Communications Medicine · 0 citations

Open access Sep 2026

Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.

The cyclin E-cyclin-dependent kinase 2 (CDK2) complex is a component of mammalian cell-cycle machinery that drives cell division. Hyperactivation of cyclin E-CDK2 is frequent in human cancers. Small-molecule CDK2 inhibitors are tested in clinical trials for cancer patients. Here, we report that cyclin E-CDK2 has a cell...

Chen Chu, Shan-Shan Zheng, Ning Mitchell et al. · Molecules and Cells · 1 citation